Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management
Immune checkpoint inhibitors are a new class of oncologic drugs that act via the inhibition of checkpoints, thereby unlocking the immune system to attack cancer cells. Their emergence has radically changed the concept of therapy in oncologic patients. However, despite their overall favorable profile...
Saved in:
Main Authors: | Zoe Apalla, PhD (Author), Bernardo Rapoport, MD (Author), Vincent Sibaud, MD (Author) |
---|---|
Format: | Book |
Published: |
Wolters Kluwer,
2021-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
by: Zoe Apalla, et al.
Published: (2021) -
Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel,
by: Jade Cury-Martins, et al.
Published: (2020) -
Lichen striatus as an immune-related adverse event following ipilimumab/nivolumab and COVID-19 infection in an adult
by: Courtney M. Kenyon, BS, et al.
Published: (2024) -
Identification of cutaneous immune-related adverse events by International Classification of Diseases codes and medication administration
by: Wenxin Chen, BS, et al.
Published: (2022) -
Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)
by: M. Yu. Fedyanin, et al.
Published: (2023)